aBLA Filing Intelligence & Biosimilar Opportunity

Rylaze

Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn

Anticancer

Intramuscular Injectable

Approval Date

30-Jun-21

Data Exclusivity Expiry

30-Jun-25

Market Exclusivity Expiry

30-Jun-33

Commercial snapshot

Market performance & projections

Revenue ($M)

403

CAGR (%)

0.0458

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

429

2027

448

2028

464

2029

482

2030

501

2031

516

2032

531

Molecule profile

Details & specifications

Molecule

Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn

Innovator

JAZZ PHARMACEUTICALS, INC.

Dosage Form

Intramuscular Injectable

Strength

10 mg/0.5 mL

Therapeutic Category

Anticancer

Usage

To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.